195 related articles for article (PubMed ID: 30940743)
1. Hypomagnesemia and Survival in Patients with Ovarian Cancer Who Received Chemotherapy with Carboplatin.
Liu W; Qdaisat A; Soliman PT; Ramondetta L; Lopez G; Narayanan S; Zhou S; Cohen L; Bruera E; Yeung SJ
Oncologist; 2019 Jun; 24(6):e312-e317. PubMed ID: 30940743
[TBL] [Abstract][Full Text] [Related]
2. Adenosine triphosphate-based chemotherapy response assay predicts long-term survival of primary epithelial ovarian cancer.
Li LY; Kim SW; Nam EJ; Lee J; Kim S; Kim YT
Int J Gynecol Cancer; 2019 Feb; 29(2):334-340. PubMed ID: 30718314
[TBL] [Abstract][Full Text] [Related]
3. Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study.
Schulz C; Heinemann V; Heinrich K; Haas M; Holch JW; Fraccaroli A; Held S; von Einem JC; Modest DP; Fischer von Weikersthal L; Kullmann F; Moehler M; Scheithauer W; Jung A; Stintzing S
Anticancer Drugs; 2020 Sep; 31(8):856-865. PubMed ID: 32639280
[TBL] [Abstract][Full Text] [Related]
4. Hypomagnesemia and survival in patients with head and neck cancers who received primary concurrent chemoradiation.
Liu W; Qdaisat A; Ferrarotto R; Fuller CD; Guo M; Meyer LA; Narayanan S; Lopez G; Cohen L; Bruera E; Hanna EY; Yeung SJ
Cancer; 2021 Feb; 127(4):528-534. PubMed ID: 33085092
[TBL] [Abstract][Full Text] [Related]
5. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
[TBL] [Abstract][Full Text] [Related]
6. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
[TBL] [Abstract][Full Text] [Related]
7. Prognostic implications of histological tumor regression (Böhm's score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma.
Rajkumar S; Polson A; Nath R; Lane G; Sayasneh A; Jakes A; Begum S; Mehra G
Gynecol Oncol; 2018 Nov; 151(2):264-268. PubMed ID: 30197060
[TBL] [Abstract][Full Text] [Related]
8. Increased incidence of severe gastrointestinal events with first-line paclitaxel, carboplatin, and vorinostat chemotherapy for advanced-stage epithelial ovarian, primary peritoneal, and fallopian tube cancer.
Mendivil AA; Micha JP; Brown JV; Rettenmaier MA; Abaid LN; Lopez KL; Goldstein BH
Int J Gynecol Cancer; 2013 Mar; 23(3):533-9. PubMed ID: 23385285
[TBL] [Abstract][Full Text] [Related]
9. Comparisons of the survival time of patients with ovarian cancer adopting post-operative chemotherapy by use of paclitaxel combined with carboplatin or nedaplatin.
Gao H; Yuan L; Han Y
World J Surg Oncol; 2016 Jun; 14(1):168. PubMed ID: 27341795
[TBL] [Abstract][Full Text] [Related]
10. Hypomagnesemia During Teriparatide Treatment in Osteoporosis: Incidence and Determinants.
Bégin MJ; Ste-Marie LG; Coupal L; Ethier J; Räkel A
J Bone Miner Res; 2018 Aug; 33(8):1444-1449. PubMed ID: 29637622
[TBL] [Abstract][Full Text] [Related]
11. Treatment Outcomes of Epithelial Ovarian Cancers Following Maximum Cytoreduction and Adjuvant Paclitaxel-Carboplatin Chemotherapy: Egyptian NCI Experience.
Nassar HR; Zeeneldin AA; Helal AM; Ismail YM; Elsayed AM; Elbassuiony MA; Moneer MM
Asian Pac J Cancer Prev; 2015; 16(16):7237-42. PubMed ID: 26514517
[TBL] [Abstract][Full Text] [Related]
12. Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy.
Gąsowska-Bodnar A; Bodnar L; Dąbek A; Cichowicz M; Jerzak M; Cierniak S; Kozłowski W; Baranowski W
Int J Gynecol Cancer; 2014 May; 24(4):687-96. PubMed ID: 24662134
[TBL] [Abstract][Full Text] [Related]
13. Identifying optimal magnesium replenishment points based on risk of severe hypomagnesemia in colorectal cancer patients treated with cetuximab or panitumumab.
Kimura M; Usami E; Teramachi H; Yoshimura T
Cancer Chemother Pharmacol; 2020 Sep; 86(3):383-391. PubMed ID: 32789758
[TBL] [Abstract][Full Text] [Related]
14. Detection of recurrence in a surveillance program for epithelial ovarian cancer.
Suprasert P; Chalapati W
Asian Pac J Cancer Prev; 2013; 14(12):7193-6. PubMed ID: 24460274
[TBL] [Abstract][Full Text] [Related]
15. Is there a high-risk subgroup of stage I epithelial ovarian cancer that is most likely to benefit from 6 versus 3 cycles of adjuvant chemotherapy?
Bakkum-Gamez JN; Richardson DL; Seamon LG; Aletti GD; Powless CA; Keeney GL; O'Malley DM; Cliby WA
Int J Gynecol Cancer; 2010 Oct; 20(7):1125-31. PubMed ID: 21495213
[TBL] [Abstract][Full Text] [Related]
16. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
[TBL] [Abstract][Full Text] [Related]
17. The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: a gynecologic Oncology Group study.
Fader AN; Java J; Krivak TC; Bristow RE; Tergas AI; Bookman MA; Armstrong DK; Tanner EJ; Gershenson DM
Gynecol Oncol; 2014 Mar; 132(3):560-5. PubMed ID: 24333362
[TBL] [Abstract][Full Text] [Related]
18. Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study.
Hess LM; Barakat R; Tian C; Ozols RF; Alberts DS
Gynecol Oncol; 2007 Nov; 107(2):260-5. PubMed ID: 17675142
[TBL] [Abstract][Full Text] [Related]
19. Progress in survival outcomes in patients with advanced ovarian cancer treated by neo-adjuvant platinum/taxane-based chemotherapy and late interval debulking surgery.
Stoeckle E; Bourdarias L; Guyon F; Croce S; Brouste V; Thomas L; Floquet A
Ann Surg Oncol; 2014 Feb; 21(2):629-36. PubMed ID: 24052318
[TBL] [Abstract][Full Text] [Related]
20. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
Meng LH; Kong BH; Zhang YZ; Yang XS; Wang LJ; Su SL; Jiang J; Cui BX; Wang B
Zhonghua Fu Chan Ke Za Zhi; 2007 Oct; 42(10):683-7. PubMed ID: 18241544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]